X. Liem

Radiomics strategies for risk assessment of tumour failure in head-and-neck cancer

Martin Vallières, Emily Kay‐Rivest, Léo Jean Perrin et al. · Scientific Reports · 2017 · 545 citations · Full text

Medicine, Nuclear Medicine, Oncology +17

Pembrolizumab versus cetuximab concurrent with radiotherapy in patients with locally advanced squamous cell carcinoma of head and neck unfit for cisplatin (GORTEC 2015-01 PembroRad): a multicenter, randomized, phase II trial

Yungan Tao, J. Biau, X.S. Sun et al. · Annals of Oncology · 2022 · 177 citations · Full text

Medicine, Oncology, Radiation Oncology +13

Avelumab–cetuximab–radiotherapy versus standards of care in locally advanced squamous-cell carcinoma of the head and neck: The safety phase of a randomised phase III trial GORTEC 2017-01 (REACH)

Yungan Tao, Anne Aupérin, Xu-Shan Sun et al. · European Journal of Cancer · 2020 · 97 citations · Full text

Medicine, Oncology, Radiation Oncology +11

LBA35 Avelumab-cetuximab-radiotherapy versus standards of care in patients with locally advanced squamous cell carcinoma of head and neck (LA-SCCHN): Randomized phase III GORTEC-REACH trial

Jean Bourhis, Yungan Tao, Xiaonan Sun et al. · Annals of Oncology · 2021 · 83 citations

Medicine, Oncology, Radiation Oncology +6

Weekly Adaptive Radiotherapy vs Standard Intensity-Modulated Radiotherapy for Improving Salivary Function in Patients With Head and Neck Cancer

J. Castelli, Juliette Thariat, Karen Bénézery et al. · JAMA Oncology · 2023 · 71 citations · Full text

Medicine, Oncology, Clinical Radiation Oncology +7